We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Nature records a paradigm shift: oncology moves from inhibitors to PROTAC and cell therapy. Find out who wins in the new race and what awaits the market.
